SCHEMBL3522957

SCHEMBL3522957

COC(=O)CCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1cccc(C)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
CCR9 P51686 2/20 0.43
FBP1 P09467 2/20 0.42
METAP2 P50579 1/20 0.40
CCR2 P41597 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
KDM1A O60341 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529261 0.91 CCR9 (0.43) CCR9METAP2CCR2KMT2ALMNA
SCHEMBL3523698 0.90 ERBB2 (0.50) CCR9CCR2ATMKMT2ALMNA
SCHEMBL3528317 0.89 SLC16A3 (0.49) FLT1FLT4KDRCCR9KMT2A
SCHEMBL3527669 0.89 LMNA (0.48) CCR9METAP2CCR2KMT2ALMNA
SCHEMBL3525803 0.88 ALDH1A1 (0.48) CCR9METAP2CCR2KMT2ALMNA
SCHEMBL3521484 0.87 SLC20A2 (0.51) CCR2KMT2ALMNAKDM1A
SCHEMBL3525865 0.86 CCR2 (0.48) CCR9CCR2KMT2ALMNAHTT
SCHEMBL3522938 0.85 ALDH1A1 (0.53) CCR9FBP1CCR2KMT2AALDH1A1
SCHEMBL3523112 0.85 CCR9 (0.42) CCR9METAP2CCR2KMT2ALMNA
SCHEMBL3521448 0.84 ACLY (0.50) CCR9LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP FLT1 165/4885FLT4 264/4885KDR 136/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG FLT1 171/4885FLT4 201/4885KDR 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.